Market Flux Event
Pharvaris Sets Q1 2027 Target for CREAATE Phase 3 Topline Data on Deucrictibant XR in Acquired Angioedema
Read this in the Market Flux appPharvaris (Nasdaq: PHVS) has flagged that topline results from Part 1 of CREAATE, its global pivotal Phase 3 study of orally administered deucrictibant extended-release tablet, are anticipated in the first quarter of 2027. The study, registered as NCT07266805, is evaluating deucrictibant XR for the prevention of attacks in patients with acquired angioedema due to C1 inhibitor deficiency, known as AAE-C1INH, a rare and potentially life-threatening condition for which oral prophylactic options remain limited.
The CREAATE readout timeline comes on the heels of Pharvaris announcing positive topline data in September 2026 from CHAPTER-3, its separate pivotal Phase 3 study of deucrictibant XR for prophylaxis of hereditary angioedema attacks. That earlier success has raised the stakes for CREAATE, which targets a distinct patient population. Pharvaris is developing deucrictibant as a bradykinin B2 receptor antagonist across multiple angioedema indications, and the company extended its cash runway into 2028 following a $132 million underwritten offering earlier in 2026.
© AI-generated summary is provided by Market Flux
Sources
- NasdaqSimplify Health Care ETF vs. VanEck Biotech ETF: One Critical Difference Could Shape Future Returns
- BioStocks$PHVS Topline data from part 1 of CREAATE pivotal Phase 3 study evaluating deucrictibant XR for the prophylaxis of AAE-C1INH attacks expected in Q1
- TheTradeXchange$MRNA - Moderna Outlines Next Phase of Growth at Analyst DayHighlights intismeran and cancer antigen therapies as foundational opportunities for a growing oncology franchiseDetails commercial and manufacturing readiness for intismeran following positive Phase 3 results in adjuvant melanomaHighlights multiple levers to improve infectious disease vaccine franchise profitabilityOutlines mid-term financial strategy focused on growth and disciplined capital allocation